Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Psychiatry Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Psychiatry Other
    FDA Requests Boxed Warnings on Conventional Antipsychotic Drugs - (DGNews)
    Pramlintide-Related Improvements in Diabetes Benefit Patients' Psyche: Presented at ADA - (DGDispatch)
    Health Canada Approves New Treatment for Bipolar Mania - (DGNews)
    Report Confirms Increased Risk of Smoking, Substance Abuse in Bipolar Adolescents - (DGNews)
    Short-Term Antipsychotics in Older Adults With Dementia Associated With Serious Adverse Events - (DGNews)

    News archive

     Recent webcasts/CME - Psychiatry Other
    • Dementia in Hispanic Americans: The Reasons Behind the Risk
    • Prevalence and Associated Factors for Suicidal Ideation and Behaviors in Obsessive-Compulsive Disorder
      Delirium Update
      The Pharmacist's Role in Breaking the Cycle of PMDD
      Understanding Autism: The Role of the Pharmacist in the Management of Autism

      Webcasts/CME archive

       Recent cases - Psychiatry Other
        Factitious Lymphoedema as a Psychiatric Condition Mimicking Reflex Sympathetic Dystrophy: A Case Report
        Topiramate-Induced Psychosis in Two Members of the One Family: A Case Report
        Childhood Autism in a 13 Year Old Boy with Oculocutaneous Albinism: A Case Report
        Unexpected Depletion in Plasma Choline and Phosphatidylcholine Concentrations in a Pregnant Woman with Bipolar Affective Disorder Being Treated with Lithuim, Haloperidol and Benztropine: A Case Report
        Recognizing Thyrotoxicosis in a Patient with Bipolar Mania: A Case Report

        Cases archive
          




        my personal edition > psychiatry other > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        Aripiprazole Efficacious for Acute Mania in Relapsing Bipolar 1 Patients: Presented at ECNP

        By Bruce Sylvester
        Special to DG News

        BARCELONA, SPAIN -- October 9, 2002 -- Aripiprazole appears to be effective and well tolerated in the treatment of acute mania in patients with bipolar disorder.

        The finding was reported here October 8 at the 15th Congress of the European College of Neuropsychopharmacology (ECNP).

        "These results suggest that aripiprazole has efficacy, is safe and is well tolerated by relapsing patients with bipolar 1 [mania] who also have acute mania or mixed episode symptoms," said lead investigator Ronald Marcus, MD, clinical investigator at Bristol-Myers Squibb, in Wallingford, United States. "We saw an excellent response to aripiprazole compared to placebo among these patients."

        The researchers enrolled 262 patients with acute, relapsing bipolar 1 mania for this phase III, multicentre, double-blind, placebo-controlled study. They randomised the subjects to aripiprazole 30 mg/day or placebo for three weeks, reducing the dose to 15 mg/day if therapeutically necessary. Patients remained hospitalised for a minimum of two weeks.

        The primary measure of efficacy was change in Young Mania Rating Scale (Y-MRS) total score. The researchers defined "response" as a decrease of 50 percent in Y-MRS total score.

        At end point, the aripiprazole group showed statistically significant improvements in Y-MRS total score compared to placebo (-8.15 versus -3.35, p=0.01 or less). The aripiprazole group also showed a significantly higher response rate compared to the placebo group (40 percent versus 19 percent, p=0.01 or less). Aripiprazole separated from placebo by day 4 for all efficacy variables.

        Both treatment groups had the same level of discontinuation of therapy and they had no significant variation in body weight.

        Aripiprazole is an investigational antipsychotic with a unique mechanism of action through partial agonism at D2 receptors, partial agonism at 5HT1A receptors, and antagonism at 5HT2A receptors.

        Bristol-Myers Squibb funded the study.



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send